Prognostic value of elevated copeptin and high-sensitivity cardiac troponin T in patients with and without acute coronary syndrome: the ConTrACS study
Aims: We aimed to assess the prognostic role of copeptin in patients presenting to the emergency department with acute symptoms and increased high-sensitivity cardiac troponin T. Methods: A total of 3890 patients presenting with acute symptoms to the emergency department of Heidelberg University Hos...
Gespeichert in:
| Hauptverfasser: | , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
11 November 2020
|
| In: |
Journal of Clinical Medicine
Year: 2020, Jahrgang: 9, Heft: 11 |
| ISSN: | 2077-0383 |
| DOI: | 10.3390/jcm9113627 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3390/jcm9113627 Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/2077-0383/9/11/3627 
|
| Verfasserangaben: | Hanna Waldsperger, Moritz Biener, Kiril M. Stoyanov, Mehrshad Vafaie, Hugo A. Katus, Evangelos Giannitsis and Matthias Mueller-Hennessen |
| Zusammenfassung: | Aims: We aimed to assess the prognostic role of copeptin in patients presenting to the emergency department with acute symptoms and increased high-sensitivity cardiac troponin T. Methods: A total of 3890 patients presenting with acute symptoms to the emergency department of Heidelberg University Hospital were assessed for increased hs-cTnT (>14 ng/L) from three cohorts: the Heidelberg Acute Coronary Syndrome (ACS) Registry (n = 2477), the BIOPS Registry (n = 320), and the ACS OMICS Registry (n = 1093). In a pooled analysis, 1956 patients remained, comprising of 1600 patients with ACS and 356 patients with non-ACS. Results: Median follow-up was 1468 days in the ACS cohort and 709 days in the non-ACS cohort. Elevated copeptin levels (>10 pmol/L) were found in 1174 patients (60.0%) in the entire cohort (58.1% in ACS and 68.5% in non-ACS, respectively) and mortality rates were significantly higher than in patients with normal copeptin levels (29.0% vs. 10.7%, p < 0.001). In a multivariate Cox regression, elevated copeptin was independently associated with all-cause death in the ACS (HR = 1.7, 1.3–2.3, p = 0.002) and non-ACS cohort (HR = 2.7, 1.4–5.0, p = 0.0018). Conclusion: Copeptin may aid in identifying patients at risk for adverse outcomes in patients with increased levels of hs-cTnT in ACS patients and in non-ACS conditions. |
|---|---|
| Beschreibung: | Gesehen am 13.01.2021 |
| Beschreibung: | Online Resource |
| ISSN: | 2077-0383 |
| DOI: | 10.3390/jcm9113627 |